Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10071867 | 0.92 | PKM (0.54) | PKMCRHR1MAPTALDH1A1KDM4E | |
| SCHEMBL15020702 | 0.92 | PKM (0.44) | PKMCRHR1TP53MAPTALDH1A1 | |
| SCHEMBL15020619 | 0.91 | PKM (0.50) | PKMCRHR1TP53MAPTALDH1A1 | |
| SCHEMBL15020739 | 0.90 | PKM (0.44) | PKMCRHR1TP53MAPTALDH1A1 | |
| SCHEMBL15021450 | 0.86 | PKM (0.39) | PKMCRHR1TP53SMN1; SMN2HTT | |
| SCHEMBL27909032 | 0.85 | HTT (0.45) | PKMCRHR1TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL15020997 | 0.84 | PKM (0.47) | PKMCRHR1MAPTALDH1A1KDM4E | |
| SCHEMBL15021005 | 0.83 | PKM (0.43) | PKMCRHR1TP53MAPTALDH1A1 | |
| SCHEMBL15021291 | 0.78 | PKM (0.41) | PKMMAPTMEN1KMT2A | |
| SCHEMBL15020933 | 0.78 | CRHR1 (0.42) | PKMCRHR1TP53MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975264-B2 | Compound acting as a cannabinoid receptor-1 inhibitor | AMOREPACIFIC CORPORATION (KR) | 2015-03-10 | — | — | US | claimed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | claimed |
| CN-103153999-A | Novel compounds as cannabinoid receptor-1 inhibitors | AMOREPACIFIC CORP | 2013-06-12 | — | — | CN | claimed |
| US-8975264-B2 | Compound acting as a cannabinoid receptor-1 inhibitor | AMOREPACIFIC CORPORATION (KR) | 2015-03-10 | — | — | US | disclosed |
| EP-2617723-A2 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | Amorepacific Corporation (KR) | 2013-07-24 | — | — | EP | disclosed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | disclosed |
| CN-103153999-A | Novel compounds as cannabinoid receptor-1 inhibitors | AMOREPACIFIC CORP | 2013-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | CNR1, CNR2, GPR18 | PKM 4702/4885CRHR1 37/4885TP53 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.